Story
American Airlines Stock Climbs as Lower Oil Prices, UBS Buy Call Outweigh BMO Target Cut

Summary
Shares of American Airlines gained in pre-market trading, buoyed by a reiterated Buy rating from UBS and a sector-wide tailwind from falling crude oil prices, which helped investors look past a price target reduction from BMO Capital.
American Airlines (NASDAQ: AAL) stock rose 1.2% in pre-market trading, supported by a bullish analyst note and easing energy costs that overshadowed a more cautious outlook from another Wall Street firm.
Conflicting Analyst Views
Analysts offered diverging perspectives on the carrier's outlook. UBS reiterated its Buy rating on the stock with a $17.00 price target, signaling confidence in the airline's trajectory. This endorsement helped fuel positive sentiment among investors.
In contrast, BMO Capital cut its price target on American Airlines to $15.50 from a previous $19.00, citing concerns over fuel cost headwinds and the pace of margin recovery. BMO maintained its Market Perform rating on the shares.
Oil Prices Provide Tailwind
A significant factor supporting airline stocks is the recent decline in crude oil prices. According to the source, easing geopolitical tensions in the Middle East have reduced the risk premium in energy markets, providing direct relief for jet fuel costs — typically the largest operating expense for carriers.
AdThis macro-economic tailwind, combined with a mildly positive tone in the broader U.S. equity markets, created a supportive environment for airline shares and other risk assets.
Context and Outlook
Despite the pre-market gains, the stock remains well below its 52-week high of $18.79, highlighting persistent investor concerns. The analyst community remains divided, with 12 buy ratings, 11 holds, and 2 sells on the stock, according to the source.
Investors are now looking ahead to the company's third-quarter earnings report. Management has previously guided for quarterly revenue growth in the range of 16% to 19%, a key metric that will be closely watched.
Read next
More on Stocks
ClearPoint Neuro Stock Plummets 24% on uniQure's Huntington's Trial Setback
Shares of ClearPoint Neuro fell sharply after its partner, uniQure, announced that its experimental gene therapy for Huntington's disease failed to meet its primary goal in a clinical trial, raising concerns about future revenue for ClearPoint's delivery technology.

Webull to Launch No-Code AI Tool for Trade Preparation via Claude, Perplexity
The online brokerage is expanding its cloud-based AI integration, allowing eligible U.S. users to research markets and prepare trades using natural language on platforms like Claude and Perplexity, without any software installation.

Iovance Biotherapeutics Raises Revenue Forecast on Strong Amtagvi Demand, Shares Surge
The biotech company boosted its full-year 2026 revenue guidance by approximately 15% at the midpoint, citing accelerating demand for its cancer therapies Amtagvi and Proleukin.

J.P. Morgan Upgrades Bureau Veritas to Overweight on Growth and M&A Outlook
J.P. Morgan raised its rating on the inspection and certification firm to “Overweight,” citing an expected recovery in organic growth driven by data centers and an increased capacity for acquisitions.